Go to:
Logótipo
Comuta visibilidade da coluna esquerda
Você está em: Start > Publications > View > Regulation of miRNA-146a and miRNA-150 Levels by Celecoxib in Premalignant Lesions of K14-HPV16 Mice
Publication

Publications

Regulation of miRNA-146a and miRNA-150 Levels by Celecoxib in Premalignant Lesions of K14-HPV16 Mice

Title
Regulation of miRNA-146a and miRNA-150 Levels by Celecoxib in Premalignant Lesions of K14-HPV16 Mice
Type
Article in International Scientific Journal
Year
2017
Authors
Rui M. Gil da Costa
(Author)
FEUP
View Personal Page You do not have permissions to view the institutional email. Search for Participant Publications View Authenticus page Without ORCID
Rita Araújo
(Author)
Other
The person does not belong to the institution. The person does not belong to the institution. The person does not belong to the institution. Without AUTHENTICUS Without ORCID
Joana M. O. Santos
(Author)
Other
The person does not belong to the institution. The person does not belong to the institution. The person does not belong to the institution. Without AUTHENTICUS Without ORCID
Mara Fernandes
(Author)
Other
The person does not belong to the institution. The person does not belong to the institution. The person does not belong to the institution. Without AUTHENTICUS Without ORCID
Tiago Neto
(Author)
Other
The person does not belong to the institution. The person does not belong to the institution. The person does not belong to the institution. Without AUTHENTICUS Without ORCID
Hugo Sousa
(Author)
Other
The person does not belong to the institution. The person does not belong to the institution. The person does not belong to the institution. Without AUTHENTICUS Without ORCID
Joana Ribeiro
(Author)
Other
The person does not belong to the institution. The person does not belong to the institution. The person does not belong to the institution. View Authenticus page Without ORCID
Margarida M. S. M. Bastos
(Author)
FEUP
View Personal Page You do not have permissions to view the institutional email. Search for Participant Publications View Authenticus page View ORCID page
Paula A. Oliveira
(Author)
Other
The person does not belong to the institution. The person does not belong to the institution. The person does not belong to the institution. Without AUTHENTICUS Without ORCID
Diogo Carmo
(Author)
Other
The person does not belong to the institution. The person does not belong to the institution. The person does not belong to the institution. Without AUTHENTICUS Without ORCID
Fátima Casaca
(Author)
Other
The person does not belong to the institution. The person does not belong to the institution. The person does not belong to the institution. Without AUTHENTICUS Without ORCID
Sandra Silva
(Author)
Other
The person does not belong to the institution. The person does not belong to the institution. The person does not belong to the institution. Without AUTHENTICUS Without ORCID
Carlos Lopes
(Author)
Other
The person does not belong to the institution. The person does not belong to the institution. The person does not belong to the institution. Without AUTHENTICUS Without ORCID
Rui Medeiros
(Author)
Other
The person does not belong to the institution. The person does not belong to the institution. The person does not belong to the institution. Without AUTHENTICUS Without ORCID
Journal
Title: Anticancer ResearchImported from Authenticus Search for Journal Publications
Vol. 37
Pages: 2913-2918
ISSN: 0250-7005
Other information
Authenticus ID: P-00M-TZ1
Resumo (PT):
Abstract (EN): Background/Aim: Human papillomavirus type 16 (HPV16) induces various types of cancer in several locations. Microenvironmental microRNAs (miRNAs) such as miRNA-146a and miRNA-150 regulate cancer-associated inflammation and are involved in HPV-induced carcinogenesis. We studied the effects of celecoxib on the expression of these two miRNAs in HPV16-induced lesions. Materials and Methods: Female transgenic (HPV16(+/-)) and wild-type (HPV16(-/-)) mice were administered 75 mg/kg/day celecoxib orally (treatment groups) or placebo (control groups) for four weeks. Skin samples were classified histologically, or used for miRNA analysis by quantitative real-time PCR. Results: HPV16(+/-) mice showed higher miRNA-146a and miRNA-150 expression levels compared to wild-type animals. Celecoxib further increased miRNA-150 (p<0.05) and miRNA-146a levels in treated animals. Celecoxib-treated HPV16(+/-) animals also showed reduced incidence of epidermal dysplasia and reduced inflammation, compared to untreated mice. Conclusion: In this model, celecoxib may be able to regulate tumour-associated inflammation, through mechanisms involving the regulation of miRNA-146a and miRNA-150.
Language: English
Type (Professor's evaluation): Scientific
No. of pages: 6
Documents
We could not find any documents associated to the publication with allowed access.
Related Publications

Of the same journal

The NF kappa B Signaling Pathway in Papillomavirus-induced Lesions: Friend or Foe? (2016)
Another Publication in an International Scientific Journal
Rui M. Gil Da Costa; Margarida M. S. M. Bastos; Rui Medeiros; Paula A. Oliveira
Vitamin D and Wnt/beta-catenin Pathway in Colon Cancer: Role and Regulation of DICKKOPF Genes (2008)
Article in International Scientific Journal
Natalia Pendas-Franco; Oscar Aguilera; Fábio Pereira; JM Gonzalez-Sancho; Alberto Munoz
Treatment and Other Healthcare Use of Breast Cancer Patients With a Previous Cancer Diagnosis (2020)
Article in International Scientific Journal
Morais, S; Costa, AR; Lopes Conceicao, L; Brandao, M; Borges, M; Araujo, N; Dias, T; Fontes, F; Pereira, S; Lunet N
The N-nitrosodiethylamine mouse model: sketching a timeline of evolution of chemically-induced hepatic lesions (2014)
Article in International Scientific Journal
Rui M. Gil da Costa; Nuno Paula Santos; Ana Faustino Rocha; Aura Colaço; Carlos Lopes; Paula A. Oliveira

See all (18)

Recommend this page Top
Copyright 1996-2025 © Faculdade de Direito da Universidade do Porto  I Terms and Conditions  I Acessibility  I Index A-Z
Page created on: 2025-07-24 at 18:59:02 | Privacy Policy | Personal Data Protection Policy | Whistleblowing